Sanchez v. Medicard Philippines
REITERATIONFacts
The Antecedents: Medicard Philippines, Inc. (Medicard) appointed Carlos Sanchez (petitioner) as its special corporate agent, granting him a commission based on "cash brought in." Through petitioner's efforts, Medicard and United Laboratories Group of Companies (Unilab) executed a Health Care Program Contract, for which petitioner received a commission. The contract was renewed, and petitioner again received a commission. Prior to the expiration of the renewed contract, Medicard proposed a premium increase, which Unilab rejected. Medicard requested petitioner to reduce his commission for the third year, but he refused. Unilab then confirmed its decision not to renew the contract. Subsequently, Unilab negotiated with Medicard for a new scheme where Unilab would pay for actual hospitalization expenses plus a service fee, under which petitioner received no commission. Petitioner demanded payment of commission and damages, but Medicard refused. Procedural History: Petitioner filed a complaint for sum of money against Medicard, Dr. Nicanor Montoya, and Carlos Ejercito. The Regional Trial Court (RTC) dismissed the complaint and the counterclaim. The Court of Appeals affirmed the RTC's decision, holding that there was no proof of a strategy to deprive petitioner of his commission, that Medicard did not commit fraud in revoking the agency, that the contract was effectively revoked when Unilab rejected the premium increase, and that an agent is not entitled to a commission when the contract is ineffectual. The Petition: Petitioner seeks reversal of the Court of Appeals' decision and resolution, arguing that the appellate court erred in holding that the agency contract was revoked, thus disentitling him to a commission.
Issue(s)
Whether the Court of Appeals erred in holding that the agency contract was revoked by Medicard, thereby disentitling the petitioner to a commission. Whether the petitioner was the efficient procuring cause of the third Health Care Program Contract between Medicard and Unilab, considering the revocation of the agency contract and the petitioner's lack of effort in procuring the third contract.
Ruling
The petition is DENIED. The challenged Decision and Resolution of the Court of Appeals in CA-G.R. CV No. 47681 are AFFIRMED IN TOTO. Costs against petitioner.
Ratio Decidendi
On the issue of revocation of agency and entitlement to commission: The Court reiterated that an agent is entitled to a commission only if they are the procuring cause of the sale. In this case, the petitioner's refusal to reduce his commission constrained Medicard to negotiate directly with Unilab, resulting in a new contract under which petitioner received no commission. The Court found that this constituted a revocation of the agency contract with petitioner, authorized by Article 1924 of the Civil Code, as Medicard directly managed the business and dealt directly with Unilab. On the issue of whether the petitioner was the efficient procuring cause of the third Health Care Program Contract: The Court found no indication that petitioner exerted any effort to renew the contract for the third time after its expiration. Therefore, he was not the agent or the "procuring cause" of the third Health Care Program Contract, and thus, not entitled to a commission. The Court cited Prats v. Court of Appeals and Manotok Brothers v. Court of Appeals regarding an agent's entitlement to commission even after the expiration of authority if they were the efficient procuring cause and took diligent steps to bring the parties together for a finalized sale, which was not the case here.
Main Doctrine
An agent is entitled to a commission only if they are the procuring cause of the sale. Where the agency contract is revoked by the principal directly dealing with third parties, the agent is not entitled to a commission, especially if the agent's refusal to reduce their commission led to the revocation.